Fig 1.
Study chart showing the number of subjects per group.
HAIC; hepatic arterial infusion chemotherapy, HCC; hepatocellular carcinoma, SORA; sorafenib.
Table 1.
Patient characteristics.
Fig 2.
Cumulative survival rates of patients treated with hepatic arterial infusion chemotherapy (HAIC)/sorafenib.
(a) In the HAIC group, survival rates at 1, 2, 3 years were 50.4, 13.2, and 13.2%, respectively. Median survival time (MST) was 12.5 months. (b) In the sorafenib group, survival rates at 1, 2, 3 years were 52.1, 19.2, and 17.3%, respectively. MST was 12.1 months.
Fig 3.
Cumulative survival rates of patients treated with hepatic arterial infusion chemotherapy based on body composition.
(a) Patients with or without muscle depletion. There were no significant differences between patients with or without muscle depletion (median survival time [MST], 15.8 vs. 10.3 months, p = 0.121). (b) Patients with high-visceral fat (H-VFA) and low-visceral fat (L-VFA). There were no significant differences between the patients with H-VFA and L-VFA (MST, 10.3 vs. 13.2 months, p = 0.371).
Table 2.
Univariate and multivariate analyses of prognostic factors in patients treated with hepatic arterial infusion chemotherapy.
Fig 4.
Cumulative survival rate of sorafenib-treated patients based on body composition.
(a) Patients with or without muscle depletion. Patients without muscle depletion showed significantly longer survival rate than those with muscle depletion (median survival time [MST], 13.4 vs. 11.0 months, p = 0.010). (b) Patients with a high visceral fat area (H-VFA) and low visceral fat area (L-VFA). Patients with H-VFA also showed significantly longer survival rate than those with L-VFA (MST, 15.0 vs. 8.4 months, p = 0.004).
Table 3.
Univariate and multivariate analyses of prognostic factors in patients treated with sorafenib.
Fig 5.
Proposed treatment strategy for advanced hepatocellular carcinoma (HCC).
HCC; hepatocellular carcinoma, H-VFA; high visceral fat area, HAIC; hepatic arterial infusion chemotherapy, ACTH; Assessment for Continuous Treatment with HAIC.